N.B.Medical focuses on creating next-generation medical devices for the treatment of cerebrovascular diseases. Its core technology blends hardware innovation—such as anti-thrombotic coating and high-precision intravascular engineering—with an in-house digital transformation and AI-powered computer modeling & simulation (CMS) platform that streamlines regulatory-compliant device development. The company aims to raise the standard of care by accelerating clinical trial readiness and ultimately deploying its products in both Japanese and overseas hospitals. Founded in October 2021 by CEO Kazuya Shobayashi, the team collaborates with institutions like UCLA and AIST to enhance R&D. Recent funding activity shows strong investor confidence: the Series B round now totals ¥3.35 billion, which includes a ¥500 million NEDO DTSU grant. Capital will be deployed to speed R&D, refine the CMS platform, and prepare for global commercialization. No revenue or user metrics have been disclosed, reflecting the company’s pre-commercial stage focus on product development.

Total raised

$5M

Funding rounds

1

Latest round

Series B

Latest activity

Mar 2026